Phaseline

Targets › GRIN2

GRIN2: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Psychiatry; next expected readout Jul 2027.

Open in Phaseline: the race on GRIN2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Institute of Mental Health (NIMH)(2R,6R)-hydroxynorketamine
Enhancer of synaptic glutamate release
GRIN1, GRIN2Phase 2SuicideJul 2027

Conditions

Suicide (1)

Modalities

small molecule (1)

Companies

National Institute of Mental Health (NIMH) (1)

Related targets

GRIN1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.